1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Tasly Pharmaceutical Group Co., Ltd
  6. Summary
    600535   CNE000001C81

TASLY PHARMACEUTICAL GROUP CO., LTD

(600535)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-06-28
10.50 CNY   -0.94%
04/25Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
03/30Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
CI
01/05Tranche Update on Tasly Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on June 26, 2021.
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
06/23/2022 06/24/2022 06/27/2022 06/28/2022 06/29/2022 Date
10.48 10.51 10.49 10.6 10.5 Last
10304530 11363670 16029790 11491940 12406130 Volume
+0.38% +0.29% -0.19% +1.05% -0.94% Change
Estimated financial data (e)
Sales 2022 8 150 M 1 216 M 1 216 M
Net income 2022 872 M 130 M 130 M
Net cash position 2022 2 286 M 341 M 341 M
P/E ratio 2022 18,2x
Yield 2022 2,70%
Sales 2023 8 677 M 1 295 M 1 295 M
Net income 2023 1 301 M 194 M 194 M
Net cash position 2023 2 301 M 343 M 343 M
P/E ratio 2023 12,2x
Yield 2023 3,75%
Capitalization 15 602 M 2 328 M 2 328 M
EV / Sales 2022 1,63x
EV / Sales 2023 1,53x
Nbr of Employees 9 437
Free-Float 51,4%
More Financials
Company
TASLY PHARMACEUTICAL GROUP CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of pharmaceutical products. The Company provides traditional Chinese medicines, chemical preparations, chemical raw materials and biological drugs. The Company's products are applied in the treatment of cardiovascular and cerebrovascular diseases, tumours, cat fever and hepatopathy, among others.... 
Sector
Pharmaceuticals
Calendar
08/19Earnings Release
More about the company
Ratings of Tasly Pharmaceutical Group Co., Ltd
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about TASLY PHARMACEUTICAL GROUP CO., LTD
04/25Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ende..
CI
03/30Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended De..
CI
01/05Tranche Update on Tasly Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced o..
CI
2021Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended ..
CI
2021Tranche Update on Tasly Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced o..
CI
2021Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended Ju..
CI
2021Tranche Update on Tasly Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced o..
CI
2021Tasly Pharmaceutical Group Co., Ltd commences an Equity Buyback Plan, under the authori..
CI
2021Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ende..
CI
2021Tasly Pharmaceutical Group Co., Ltd's Equity Buyback announced on April 25, 2020, has e..
CI
2021Tranche Update on Tasly Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced o..
CI
2020Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended ..
CI
2020Tranche Update on Tasly Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced o..
CI
2020Tasly Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended Ju..
CI
2020Chongqing Pharmaceutical Co., Ltd. completed the acquisition of Tianjin Tasly Medicine ..
CI
More news
News in other languages on TASLY PHARMACEUTICAL GROUP CO., LTD
04/25Tasly Pharmaceutical Group Co., Ltd annonce ses résultats pour le premier trimestre clo..
03/30Tasly Pharmaceutical Group Co., Ltd. annonce ses résultats financiers pour l'année comp..
2020Tasly Pharmaceutical Group Co., Ltd. met en place une distribution d'intérêts en 2019, ..
2018BIOTECH TIME : Quantum, Noxxon, Onxeo et Cerenis se dévoilent au T4, Transgène et la manne..
2018TRANSGENE : 10 juillet 2018 - Transgene et Tasly Biopharmaceuticals signent plusieurs acco..
More news
Chart TASLY PHARMACEUTICAL GROUP CO., LTD
Duration : Period :
Tasly Pharmaceutical Group Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TASLY PHARMACEUTICAL GROUP CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 4
Last Close Price 10,50 CNY
Average target price 11,44 CNY
Spread / Average Target 8,93%
EPS Revisions
Managers and Directors
Jing Su Director
Jie Wei Chief Financial Officer
Kai Jing Yan Chairman
Zheng Liang Ye Chairman-Supervisory Board
Ai Jian Wang Independent Director